These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 26832796)

  • 1. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
    Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
    Kojima K; Maeda A; Yoshimura M; Nishida Y; Kimura S
    Oncotarget; 2016 Oct; 7(43):69625-69637. PubMed ID: 27626308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.
    Chen L; Zhao Y; Halliday GC; Berry P; Rousseau RF; Middleton SA; Nichols GL; Del Bello F; Piergentili A; Newell DR; Lunec J; Tweddle DA
    Br J Cancer; 2014 Aug; 111(4):716-25. PubMed ID: 24921920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
    Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
    Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53
    Chamberlain V; Drew Y; Lunec J
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
    Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
    Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.